15. 封入体筋炎 Inclusion body myositis Clinical trials / Disease details
臨床試験数 : 42 / 薬物数 : 60 - (DrugBank : 16) / 標的遺伝子数 : 12 - 標的パスウェイ数 : 123
Showing 1 to 10 of 36 diseases
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05272969 (ClinicalTrials.gov) | March 31, 2022 | 28/1/2022 | Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease | Pompe & Pain - Observational Study to Assess Musculoskeletal Pain in Late-onset Pompe Disease (LOPD) Pompe & Pain - Observational Study to Assess Musculoskeletal Pain in Late-onset Pompe Disease (LOPD) ... | Pompe Disease (Late-onset);Inclusion Body Myositis;Spinal Muscular Atrophy Type 3;FSHD | Diagnostic Test: Beck depression inventory fast screen (Questionnaire);Diagnostic Test: Brief Pain Inventory (BPI) (Questionnaire);Diagnostic Test: German Pain Inventory (Questionnaire);Diagnostic Test: Fatigue Severity and Disability Scale (FSS) (Questionnaire);Diagnostic Test: Rotterdam Handicap Scale (RHS) (Questionnaire);Diagnostic Test: R-PAct (Questionnaire);Diagnostic Test: Quick Motor Function Test;Diagnostic Test: Handheld Dynamometry (HHD);Diagnostic Test: Six-minute walk test (6MWT);Diagnostic Test: Pressure pain threshold;Diagnostic Test: Muscle ultrasound;Diagnostic Test: Vital signs;Diagnostic Test: Borg Scale;Diagnostic Test: Laboratory assessment: Creatine kinase;Diagnostic Test: Laboratory assessment: Vitamin D Level;Diagnostic Test: Laboratory assessment: calcium;Diagnostic Test: Laboratory assessment: magnesium;Diagnostic Test: Laboratory assessment: phosphate;Genetic: Genetic test: ACE polymorphism;Genetic: Genetic test: ACTN3 polymorphism;Genetic: Blood draw for optional genetic exome sequencing Diagnostic Test: Beck depression inventory fast screen (Questionnaire);Diagnostic Test: Brief Pain I ... | LMU Klinikum | NULL | Not yet recruiting | 18 Years | N/A | All | 95 | Germany | |
2 | NCT05032131 (ClinicalTrials.gov) | September 2021 | 27/8/2021 | Cell Therapy for IBM by Muscle Injection of ADSVF: a Phase I Trial | Cell Therapy for Inclusion Body Myositis (IBM) by Muscle Injection of Autologous Uncultured Adipose-Derived Stromal Vascular Fraction (ADSVF): a Phase I Trial Cell Therapy for Inclusion Body Myositis (IBM) by Muscle Injection of Autologous Uncultured Adipose- ... | Inclusion Body Myositis | Biological: ADSVF | Assistance Publique - Hôpitaux de Paris | NULL | Not yet recruiting | 45 Years | 80 Years | All | 32 | Phase 1 | NULL |
3 | NCT04659031 (ClinicalTrials.gov) | May 25, 2021 | 25/11/2020 | A Phase 1 Study of ABC008 in Adult Patients With Inclusion Body Myositis (IBM) | A Phase 1, Open-Label, Ascending Dose Study of ABC008 in Adult Patients With Inclusion Body Myositis (IBM) A Phase 1, Open-Label, Ascending Dose Study of ABC008 in Adult Patients With Inclusion Body Myositis ... | Inclusion Body Myositis | Drug: ABC008 | Abcuro, Inc. | NULL | Recruiting | 40 Years | N/A | All | 27 | Phase 1 | Australia |
4 | NCT04421677 (ClinicalTrials.gov) | August 20, 2020 | 18/5/2020 | Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis | Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis | Inclusion Body Myositis;Sporadic Inclusion Body Myositis | Drug: Phenylbutyrate Oral Tablet | University of Kansas Medical Center | NULL | Active, not recruiting | 18 Years | N/A | All | 10 | Phase 1 | United States |
5 | EUCTR2019-000749-11-GB (EUCTR) | 09/10/2019 | 20/06/2019 | An open-label, non-randomized trial to investigate the efficacy and safety of early versus delayed start of arimoclomol in patients with sporadic inclusion body myositis who have completed the IBM4809 trial An open-label, non-randomized trial to investigate the efficacy and safety of early versus delayed s ... | An open-label, non-randomized trial to investigate the efficacy and safety of early versus delayed start of arimoclomol in patients with sporadic inclusion body myositis who have completed the IBM4809 trial. An open-label, non-randomized trial to investigate the efficacy and safety of early versus delayed s ... | Sporadic Inclusion Body Myositis (sIBM) MedDRA version: 21.1;Level: LLT;Classification code 10075052;Term: Sporadic inclusion body myositis;System Organ Class: 100000004859;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03] Sporadic Inclusion Body Myositis (sIBM) MedDRA version: 21.1;Level: LLT;Classification code 10075052 ... | Product Name: Arimoclomol Product Code: BRX-345 INN or Proposed INN: ARIMOCLOMOL Other descriptive name: Arimoclomol citrate Product Name: Arimoclomol Product Code: BRX-345 INN or Proposed INN: ARIMOCLOMOL Other descriptive name ... | Orphazyme A/S | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 130 | Phase 3 | United States;United Kingdom | ||
6 | NCT03710941 (ClinicalTrials.gov) | February 19, 2019 | 15/10/2018 | Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis | A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intravenously Administered REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intraveno ... | Sporadic Inclusion Body Myositis | Drug: REGN2477+REGN1033;Drug: Matching placebo | Regeneron Pharmaceuticals | NULL | Withdrawn | 45 Years | 75 Years | All | 0 | Phase 2 | NULL |
7 | EUCTR2017-004903-33-GB (EUCTR) | 18/06/2018 | 05/04/2018 | Study of Arimoclomol in patients with Inclusion Body Myositis (IBM) | Phase 2/3 Study of Arimoclomol in Inclusion Body Myositis (IBM)A Randomized, Double-blind, Placebo-Controlled Trial Phase 2/3 Study of Arimoclomol in Inclusion Body Myositis (IBM)A Randomized, Double-blind, Placebo-C ... | Sporadic Inclusion Body Myositis (sIBM) MedDRA version: 21.1;Level: LLT;Classification code 10075052;Term: Sporadic inclusion body myositis;System Organ Class: 100000004859;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03] Sporadic Inclusion Body Myositis (sIBM) MedDRA version: 21.1;Level: LLT;Classification code 10075052 ... | Product Name: Arimoclomol Product Code: BRX-345 INN or Proposed INN: ARIMOCLOMOL Other descriptive name: Arimoclomol citrate Product Name: Arimoclomol Product Code: BRX-345 INN or Proposed INN: ARIMOCLOMOL Other descriptive name ... | Orphazyme A/S | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 150 | Phase 2;Phase 3 | United States;United Kingdom | ||
8 | NCT03440034 (ClinicalTrials.gov) | May 22, 2018 | 14/11/2017 | Study of Pioglitazone in Sporadic Inclusion Body Myositis | An Open-Label Pilot Study of Pioglitazone in Sporadic Inclusion Body Myositis | Myositis;Inclusion Body Myositis;Muscular Diseases;Musculoskeletal Disease;Neuromuscular Diseases;Nervous System Diseases Myositis;Inclusion Body Myositis;Muscular Diseases;Musculoskeletal Disease;Neuromuscular Diseases;Ne ... | Drug: Pioglitazone | Johns Hopkins University | NULL | Completed | 50 Years | N/A | All | 19 | Phase 1 | United States |
9 | EUCTR2015-001411-12-DK (EUCTR) | 10/11/2015 | 11/09/2015 | Extension study to evaluate the long-term efficacy, safety and tolerability of BYM338 in patients with sporadic inclusion body myositis Extension study to evaluate the long-term efficacy, safety and tolerability of BYM338 in patients wi ... | Extension of the CBYM338B2203 phase IIb/III study to evaluate the long-term efficacy, safety and tolerability of intravenous BYM338 in patients with sporadic inclusion body myositis Extension of the CBYM338B2203 phase IIb/III study to evaluate the long-term efficacy, safety and tol ... | Sporadic Inclusion Body Myositis MedDRA version: 18.1;Level: PT;Classification code 10066407;Term: Inclusion body myositis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Sporadic Inclusion Body Myositis MedDRA version: 18.1;Level: PT;Classification code 10066407;Term: I ... | Product Code: BYM338 INN or Proposed INN: Bimagrumab | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 240 | Phase 3 | France;United States;Belgium;Australia;Denmark;Netherlands;Japan;Italy;United Kingdom;Switzerland | ||
10 | EUCTR2015-001411-12-BE (EUCTR) | 09/11/2015 | 12/10/2015 | Extension study to evaluate the long-term efficacy, safety and tolerability of BYM338 in patients with sporadic inclusion body myositis Extension study to evaluate the long-term efficacy, safety and tolerability of BYM338 in patients wi ... | Extension of the CBYM338B2203 phase IIb/III study to evaluate the long-term efficacy, safety and tolerability of intravenous BYM338 in patients with sporadic inclusion body myositis Extension of the CBYM338B2203 phase IIb/III study to evaluate the long-term efficacy, safety and tol ... | Sporadic Inclusion Body Myositis MedDRA version: 18.0;Level: PT;Classification code 10066407;Term: Inclusion body myositis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Sporadic Inclusion Body Myositis MedDRA version: 18.0;Level: PT;Classification code 10066407;Term: I ... | Product Code: BYM338 INN or Proposed INN: Bimagrumab | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 240 | Phase 3 | France;United States;Belgium;Denmark;Australia;Netherlands;Japan;Italy;United Kingdom;Switzerland |